Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your post falls on deaf ears, like I told you. There is no reprieve for you. You have acted in bad conscience for years. You have failed with all of your desceptions. You are the enemy and antagonist of the shareholders. Always have been. Always will be!
NOTHING WILL ERASE YOUR HISTORY AT ALL! "NOTHING"!!!!!!
Viking65, you don't have to wonder, just don't believe me. I know what I say and where I stand, and that is good enough for me. What I have done and what I have posted I did in good conscience and I do not regret a single one of my statements and/or opinions, as I do not intend to rewrite the history of Loch/CDEX. What was once wrong was wrong, and no future success can erase the history. Today CDEX is showing a different picture, a more promising one, I am not blind or stupid as to not see it and acknowledge it.
Gee I wonder why I don't believe a word you say Liviu? Then again I don't wonder, because I know who you are! What you have done! What you have posted! Etc., etc., etc. Case closed. Don't bother to reply, it will fall on deaf ears. Especially mine.
Indeed, today's news and SEC filing are a great step in the right direction. Evidently, the presence of Griffin at the helm of the operations at CDEX have caused positive events to be achieved. I hope and pray that the trend continues and that, eventually ex Loch shareholders may in the not to distant future receive the reward for their sacrificial patience.
Congratulations are due to MP and the CDEX team.
To All: THIS IS IMPORTANT FROM THE 8K.
The news keeps getting better and better and I really do not believe we've seen the best of it in the pharmaceutical arena ...or in Homeland Security.
My eyes are bleary from reading the 8-K, but one clause should shut some of the bashers up pretty good. Casey/Rottenaplle, Elmo and others have been stating that we have not and will never be able to obtain product liabilty insurance. Looks like that issue is specifically addressed and answered in the 8-K:
10.4 Insurance. During the term of this Agreement, CDEX and Baxa each
shall maintain its own respective product liability insurance with respect to
the Products, in such amounts and with such scope of coverage as each Party
reasonably determines are adequate to cover such Party's likely obligations
under this Agreement and as are appropriate for companies of like size, taking
into account the scope of activities contemplated herein. In the alternative,
Baxa may elect to self-insure all or part of the limits described above under a
self-insurance program customary for the industry in which Baxa does business.
Makes sense, Baxa can afford to self insure if they choose. CDEX will have product liability insurance.
By the way, it is standard practice in these agreements to treat as confidential information pricing and the number of units to be purchased, etc.
This stock should gap up again tommorrow and just keep going up. So long $1.10--hello $2.00!!!!!!
8K JUST OUT.
Effective November 7, 2005, CDEX Inc. entered into a strategic distribution
agreement with Baxa Corporation. The agreement provides for Baxa to be the
exclusive distributor of CDEX's ValiMed solution for medication verification for
healthcare organizations in the United States and Canada. The agreement calls
for purchase of a fixed number of ValiMed units by Baxa for two years, as well
as goals that must be met in order to maintain the Baxa exclusive distribution
rights. Baxa is also to have the non-exclusive right to distribute the ValiMed
device in the US and Canada to entities other than the specified healthcare
organizations. Baxa has the exclusive right to sell support, accessories and
chemical signatures (for particular medications) for devices which it has sold
under the agreement. CDEX has retained the right to provide such support,
accessories and signatures for devices sold outside of Baxa's territory or for
products other than the ValiMed solution.
The parties are to bear their own marketing and advertising expenses with
respect to the products, and Baxa is to use reasonable efforts to promote the
products within its territory, including media advertising, trade show
attendance and assignment of a trained sales representative. It may include them
in multi-product promotions with CDEX's prior written approval. Baxa must obtain
CDEX's consent to any Baxa promotional materials regarding the products that
contain CDEX's marks or claims related to the products. Baxa is to control
product pricing and pricing strategy with respect to products sold by it.
Specifications, indications, labeling and packaging for the products and
accessories remain within CDEX's sole discretion, subject to compliance with
government regulation and notice to and approval of Baxa of any changes prior to
shipping.
The agreement contains standard representations and warranties for an agreement
of its type, including a representation by CDEX that the devices, the
accessories, the CDEX marks and promotional materials do not infringe any
patent, copyright, trademark or other proprietary right of any third parties
which representation is supported by a limited indemnification.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
10.1 Reseller Agreement, dated as of November 7, 2005, by and between the
Registrant and Baxa Corporation
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
CDEX INC.
Date: November 14, 2005 By: /s/ Malcolm H. Philips
----------------------
Malcolm H. Philips
CEO/President
3
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101.txt
<TEXT>
Exhibit 10.1
Execution Copy
RESELLER AGREEMENT
This Distribution Agreement (this "Agreement") is entered into as of
the 7th day of November 2005 (the "Effective Date") by and between Baxa
Corporation, a Colorado corporation, having its principal offices at 1445
Grasslands Drive, Englewood, Colorado 80112-3903 ("Baxa") and CDEX, Inc., a
Nevada corporation, maintaining its principal place of business at 1700
Rockville Pike, Suite 400, Rockville, MD 20852 ("CDEX").
WITNESSETH:
WHEREAS, CDEX manufactures a medication validation system; and
WHEREAS, CDEX and Baxa wish to enter into this Agreement to enable Baxa
to purchase from CDEX, and to promote, market, offer for sale, sell and
distribute the Products (as hereinafter defined) in the Territory (as
hereinafter defined) during the Term (as hereinafter defined).
NOW, THEREFORE, in consideration of the mutual promises, covenants, and
agreements set forth herein, CDEX and Baxa agree as follows:
ARTICLE 1 DEFINITIONS
The following words and phrases, when used herein with initial capital
letters, shall have the meanings set forth or referenced below:
1.1 "Accessories" means Cuvettes and any other accessories relating to
the Device.
1.2 "ADR" means the alternative dispute resolution process referred to
in Section 13.6.
1.3 "Affiliate" means, with respect to a Party, any person or entity
that controls, is controlled by or is under common control with such Party. An
entity or person shall be deemed to be in control of another entity (controlled
entity) if the former owns directly or indirectly at least fifty percent (50%)
of the outstanding voting equity of the controlled entity (or other equity or
ownership interest in the event that such controlled entity is other than a
corporation).
1.4 "Annual Support" means the maintenance and support program
provided by CDEX with respect to each Device as described in Exhibit 1.4.
1.5 "Base Pack" means the base pack of [ * ] Signatures (to be
mutually determined by the Parties) included with each Device.
1.6 "Baxa Marks" means the corporate names "Baxa," "Baxa Corporation,"
trade names and logos of Baxa and all derivatives of the foregoing.
* The omitted information is confidential and is being filed separately with
the Securities and Exchange Commission.
1
<PAGE>
Execution Copy
1.7 "Baxa Promotional Efforts" means all of Baxa's activities to
promote the Products pursuant to the terms of Article 3 or as otherwise
specifically agreed to by Baxa in writing.
1.8 "Baxa Promotional Materials" means all advertising (in any form),
printed or electronic matter, including printed literature and reprints or
graphic matter produced by or at the request of Baxa relating or referring to
the Products that contain CDEX's Mark or claims related to the Products for
distribution to customers and others in connection with the Baxa Promotional
Efforts.
1.9 "Baxa Representative" means an individual that: (a) is a full-time
employee and sales person of Baxa; and (b) is qualified and has been trained by
Baxa to make sales presentations for Baxa's products; and (c) is qualified and
has been appropriately trained by Baxa to make effective sales presentations for
the Products.
1.10 "Business Day" means any day of the week which is not a Saturday,
Sunday or legal holiday observed by the federal government of the United States
or a state of the United States which is the primary place of business of either
Party.
1.11 "Calendar Year" means twelve (12) consecutive months commencing
on the Effective Date of this Agreement.
1.12 "CDEX Marks" means the names "CDEX", "ValiMed" and any other
trademarks, trade names, service marks and logos of CDEX and all derivations of
the foregoing that CDEX approves for use in connection with the Products.
1.13 "CDEX Promotional Materials" means all advertising (in any form),
printed matter, including printed literature and reprints or graphic matter
relating or referring to the Products that are prepared by or for CDEX.
1.14 Reserved.
1.15 "Confidential Information" means, for each Party, any and all
information disclosed by one Party to the other Party in writing which is
clearly marked as "CONFIDENTIAL" or which is disclosed orally and indicated at
the time as confidential or designated in writing as confidential within thirty
(30) days after such disclosure, except any portion thereof which:
(a) is lawfully known to the receiving Party at the time of
disclosure, as evidenced by its written records;
(b) is disclosed to the receiving Party by a Third Party
having a legal right to make such disclosure;
(c) becomes published or otherwise part of the public domain
through no fault of the receiving Party; or
2
<PAGE>
Execution Copy
(d) is independently developed by or for the receiving Party
without recourse to the other Party's Confidential Information disclosed
hereunder, as reasonably documented or otherwise reasonably provable.
1.16 "Cuvette" means CDEX's D-Tube cuvettes and any new version,
upgrade or improvement thereof or replacement therefor, for use with the Device
or any New Product.
1.17 "Device" means CDEX's Valimed Cuvette D-Tube device and any new
version, upgrade or improvement thereof, together with the Base Pack.
1.18 "Device Action" has the meaning set forth in Section 7.2.
1.19 "Effective Date" has the meaning set forth in Section 9.1.
1.20 "Extension Term" means the period of time after the end of the
Initial Term for which the Parties have extended the Term, in accordance with
the provisions of Section 9.2.
1.21 "Forecast" has the meaning set forth in Section 5.11.
1.22 "Initial Devices" has the meaning set forth in Section 5.2(b).
1.23 "Initial Term" has the meaning set forth in Section 9.2.
1.24 "Marks" means, individually and collectively, the CDEX Marks and
the Baxa Marks.
1.25 "New Product" means any new medication validation system, cuvette
or other Accessory developed or acquired by CDEX during the Term that replaces
any Product.
1.26 "Party" means either Baxa or CDEX, and their respective
successors and permitted assigns, and "Parties" shall mean Baxa and CDEX and
their respective successors and permitted assigns.
1.27 "Products" means individually each of, and collectively, all of,
the Device, and the Signatures, the Accessories and Annual Support associated
with the Device.
1.28 "Promotional Material" means individually and collectively the
Baxa Promotional Material and the CDEX Promotional Material.
1.29 "Protocols" means the most current protocols provided by CDEX to
Baxa regarding the proper handling, storage, shipment and use of the Products,
provided that such Protocols shall not take effect until not less than thirty
(30) days after receipt by Baxa.
1.30 "Purchase Orders" has the meaning set forth in Section 5.2(a).
1.31 "Purchase Targets" has the meaning set forth in Section 3.4.
3
<PAGE>
Execution Copy
1.32 "Regulatory Agency" means any agency, authority or instrumentality
of the United States of America, any state, commonwealth, territory or
possession thereof, Canada, any province or territory thereof, or any political
subdivision or any of the foregoing that has any regulatory authority with
respect to the Products.
1.33 "Renewal Date" has the meaning set forth in Section 9.2.
1.34 "Signatures" means CDEX's spectral signatures used to identify
medications.
1.35 "Specifications" means, with respect to any Product, CDEX's
written specifications for such Product which specifications are in effect at
the time of manufacture of such Product.
1.36 "Term" means the period of time on and after the Effective Date
until the later of: (a) the end of the Initial Term; and (b) the end of the
Extension Term.
1.37 "Territory" means all hospitals, compounding pharmacies and
physicians' offices located in the fifty states of the United States including
the District of Columbia, and all territories, commonwealths and possession
thereof, including Puerto Rico, and Canada.
1.38 "Third Party" means a natural person, corporation, partnership,
trust, joint venture, governmental authority or other legal entity or
organization other than the Parties and their Affiliates.
1.39 "Transfer Price" shall mean the price for Devices that Baxa shall
pay to CDEX pursuant to Section 5.7, as further defined therein.
ARTICLE 2 GRANT OF DISTRIBUTION RIGHTS
2.1 Grant. Subject to the terms and conditions of this Agreement, CDEX
hereby grants to Baxa (a) the exclusive right, even as to CDEX, (with the right
to sublicense to its wholesalers and distributors) to market, promote, offer for
sale, sell and distribute the Products in the Territory during the Term and (b)
the non-exclusive right to market, promote, offer for sale, sell and distribute
the Products within the healthcare sector in the U.S. and Canada but outside of
the Territory during the Term. For the avoidance of doubt, Baxa shall only have
the exclusive right to sell Accessories, Signatures and Support for use with a
Device previously sold by Baxa within its exclusive Territory pursuant to this
Agreement, and CDEX shall be free to sell Accessories, Signatures and Support
for use with the sales of Devices outside the Territory and for use with
products other than the Devices. Notwithstanding the preceding, Baxa shall only
market, promote, offer for sale, sell and distribute the Products within Canada
once CDEX has notified Baxa in writing that CDEX has obtained any and all
required permits, licenses and approvals needed for distribution of the Products
within Canada. No other rights with respect to the Products are granted by CDEX
to Baxa except as expressly granted in this Agreement. Nothing in this Section
2.1 shall prohibit CDEX from (i) completing sales of any Products to those
entities specified in Exhibit 2.1, which Baxa acknowledges and agrees were in
progress as of the Effective Date; provided, however that if such sales are not
4
<PAGE>
Execution Copy
consummated on or before [ * ], CDEX shall cease all such sales activities and
fully cooperate with Baxa so that Baxa may make such sales; or (ii) continuing
to sell Accessories, Signatures and Support for use with Devices that were
either sold by CDEX to other customers prior to the Effective Date or that are
sold pursuant to subsection (i) of this sentence prior to [ * ]. The Parties
shall use reasonable efforts to coordinate all sales efforts outside of the
Territory.
2.2 Marketing. Each Party shall bear its own expenses in connection
with the marketing, sales, promotion and advertising of the Products. CDEX shall
have no obligation to market, sell, promote or advertise the Products. Baxa
shall have the right to include the Products in any multi-product promotion, if
and as Baxa deems appropriate; provided, that Baxa shall obtain CDEX's prior
written approval for any Promotional Material used in connection with any such
multi-product promotion, if such material contains any CDEX Marks or contains
claims related to the Products, all in accordance with Article 6.
2.3 New Products. In the event, during the Term CDEX discontinues
production of any Product and there is a New Product which replaces such
Product, CDEX shall offer the New Product on such terms and conditions as the
Parties may agree. The Parties acknowledge and agree that CDEX is required to
produce and support the Product under the terms of this Agreement or fairly
negotiate access to the New Product.
ARTICLE 3 BAXA'S RESPONSIBILITIES
3.1 Marketing; Trade Shows. Baxa will use reasonable efforts to
promote and market sales of the Products within the Territory. Baxa, in its
discretion, will exhibit the Products at a reasonable number of trade shows,
meetings, events and places where Baxa deems it appropriate in the Territory.
Baxa will reasonably advertise the Products in appropriate media channels as
needed to promote the sales of the Products within the Territory. Baxa will
assign sufficient Baxa Representatives skilled in the capabilities of the
Products to reasonably achieve the sales goals for the Products contained in
this Agreement.
3.2 Product Pricing. For Products that Baxa sells in the Territory,
Baxa shall solely formulate and control all Product prices, pricing strategies
and, subject to Section 3.9, terms of sale for the Products.
3.3 Reports. Baxa will provide CDEX a written statement on a quarterly
basis, identifying the quantity and price of Products sold by Baxa to customers
under this Agreement. conscientious
3.4 [ * ]
3.5 Products. Baxa shall comply in all respects with all applicable
laws, rules and regulations regarding the sale, storage, shipment, marketing and
promotion of the Products. Baxa shall avoid any deceptive, misleading or
unethical practices, or any false advertising, in connection with its sales and
distributing activities under this Agreement.
* The omitted information is confidential and is being filed separately with
the Securities and Exchange Commission.
5
<PAGE>
Execution Copy
3.6 Communications with Regulatory Agencies. Baxa shall promptly
communicate to CDEX all material matters communicated between Baxa and any
applicable Regulatory Agency that relate to the Products. Baxa shall endeavor to
limit such communications to matters that it is required by law to discuss with
such an agency.
3.7 Export Control. Baxa will not export or re-export (directly or
indirectly) any of the Products or documentation or other technical data
associated therewith without complying with the U.S. Export Administration Act
of 1979 (as amended) or any replacement act, and the regulations promulgated
thereunder.
3.8 Sub-Resellers. If Baxa engages any other reseller or distributor
to distribute the Products within the Territory, Baxa shall first enter into a
written agreement with each such reseller or distributor that contains license
restrictions, intellectual property protections, confidentiality obligations and
indemnification obligations and other provisions protecting CDEX that are no
less protective or restrictive, as applicable, than those set forth in this
Agreement. In addition, any such distribution agreement must include a provision
(i) obligating the distributor/reseller to agree that CDEX shall have no
liability of any kind, direct or otherwise, arising out of or related to the
distribution agreement between Baxa and such distributor/reseller; (ii)
obligating the distributor/reseller to enter into a customer agreement with each
customer of the Products that contains similar protections for CDEX with respect
to such customer; and (iii) designating CDEX as a third party beneficiary of
such distribution agreement.
3.9 Proper Use. Baxa shall ensure that it and its other distributors
and resellers do not promote the use of the Products for any purpose other than
the purposes specified in the Specifications, the CDEX Promotional Materials or
the Baxa Promotional Materials as approved by CDEX. Baxa shall, in its end user
agreements notify, or require its distributors and resellers in their end user
agreements to notify, (as applicable), all customers of the Products of the
permitted applications and uses of the Products and to state that non-specified
uses are prohibited. Baxa acknowledges that uses of the Product beyond those
specified in the Specifications, the CDEX Promotional Materials or the Baxa
Promotional Materials as approved by CDEX may require further governmental or
regulatory approvals, and may subject the Parties to increased regulation. CDEX
shall have no liability to Baxa for any claims or regulatory fines, penalties or
action taken as a result of Baxa's breach of this Section 3.09.
3.10 Commercial Software Designation. In distributing Products to U.S.
government customers, Baxa shall ensure that the software components of the
Products are identified as commercial computer software. In the case of sales of
the Products to non-defense agencies of the U.S. Government, Baxa shall also
ensure that the customer contract incorporates either (i) FAR 52.227-19
(Commercial Computer Software--Restricted Rights) or (ii) FAR 52.227-7014
(Rights in Data--General) with Alternate III. If clause 52.227-19 is
incorporated, Baxa shall (i) mark the software and its documentation as follows:
Restricted Computer Software
Notice--Notwithstanding any other lease or license agreement that may
pertain to, or accompany the delivery of, this computer software, the
rights of the Government regarding its use, reproduction and disclosure
are as set forth in Government Contract No. ____________.
6
<PAGE>
Execution Copy
and (ii) include the following addendum with any copyright legend on the
software or its documentation:
Unpublished--rights reserved under the copyright laws of the United
States.
If clause 52.227-7014 is incorporated in the customer contract, Baxa
shall mark the software and its documentation with a Restricted Rights Notice as
specified in Alternate III of that clause.
3.11 Restrictions. Except as provided in Section 3.10, Baxa shall not
(i) modify, alter, repair, replace or otherwise change the Products or any
component to be distributed by Baxa hereunder without CDEX's prior written
consent; and (ii) decompile or disassemble, or reverse engineer the Products or
any component thereof in order to obtain the source code for any software or
otherwise access the trade secrets or functionality of the Products.
ARTICLE 4 CDEX'S RESPONSIBILITIES
4.1 Products Specifications. The Specifications, indications, labeling
and packaging for the Device, the Cuvette and other Accessories shall be within
the sole discretion of CDEX; provided, that CDEX may change any of the foregoing
only if: (a) CDEX files all necessary submissions required by any applicable
Regulatory Agency and obtains all necessary approvals of such Regulatory Agency,
if any, in order to market the Products in the United States or Canada; and (b)
notifies Baxa of and obtains Baxa's approval (which approval shall not be
unreasonably withheld) for such change prior to shipping such Products to Baxa.
In the event that CDEX notifies Baxa of a change that Baxa reasonably believes
is unacceptable, as Baxa's sole remedy, Baxa shall have the right to remove such
Product from this Agreement and cancel any outstanding Purchase Orders for the
Product without incurring any liability for such cancelled orders. All costs of
such changes shall be borne by CDEX; provided, that, to the extent reasonably
requested by CDEX, Baxa shall revise all Baxa Promotional Materials to reflect
any such changes; and provided, further, that all costs associated with such
revised Baxa Promotional Materials are divided equally between the Parties.
4.2 Communications with Regulatory Agencies. CDEX shall promptly
communicate to Baxa all material matters communicated between CDEX and any
applicable Regulatory Agency that relate to any Product to the extent that such
communication affects Baxa, Baxa's customers or the sale or use of the Products
in the Territory. The preceding shall not apply to the extent of any privileged
information or sensitive information the disclosure of which would put CDEX at
increased liability risk, unless CDEX is required by law to disclose such
information anyway or unless any such information pertains to health or safety
issues relating to the Products.
7
<PAGE>
Execution Copy
4.3 Regulatory Matters. CDEX shall be solely responsible for, and bear
the cost of, all regulatory matters applicable to its business regarding the
Products required for Baxa to market and sell the Products in the Territory.
Baxa shall be solely responsible for, and bear the cost of, all regulatory
matters applicable to its business as needed for Baxa to operate as a
distributor of the Products within the Territory.
4.4 Product Manufacture. CDEX shall manufacture, or have manufactured,
the Products in accordance with industry standards and the Specifications for
the Products, if any, and shall be responsible for all product liability and
quality assurance issues with respect to the Products caused solely by CDEX, or
its agents or its subcontractors engaged in connection with the manufacture of
the Products, subject to any exclusions set forth in Section 10.1. Baxa shall be
responsible for any product liability and quality assurance issues caused solely
by Baxa or its resellers and distributors, subject to any exclusions set forth
in Section 10.2. CDEX shall comply in all respects with all applicable federal
laws, rules and regulations regarding the manufacture, labeling, advertising and
packaging of the Products.
4.5 Warranty; Annual Support. CDEX warrants that each Device delivered
to Baxa or any of its end user customers pursuant to this Agreement shall, for a
period of ninety (90) days following the date of delivery of such Device to the
applicable end user, perform in accordance with the Specifications and be free
from defects in material and workmanship. In the event of breach of such
warranty during the warranty period, CDEX shall, at its option and expense, and
as Baxa's exclusive remedy for such breach, either repair or replace the
non-conforming Device in order to bring it into compliance with the foregoing
warranty. CDEX shall have no obligation to repair or replace any non-conforming
Device to the extent such non-conformity is attributable to any of the
exceptions stated in Section 2 of Exhibit 1.4. After expiration of the foregoing
ninety-day warranty period, CDEX shall provide Annual Support services for any
Device purchased by Baxa hereunder, to the extent that Baxa purchases Annual
Support services from CDEX for such Device, all in accordance with the terms set
forth in Exhibit 1.4. Baxa shall provide first level support, handling initial
customer complaints. If Baxa is not able to resolve the complaint in the initial
contact, Baxa shall provide CDEX with prompt written notice of such complaint
and CDEX shall provide such Annual Support as may be necessary to resolve the
complaint in accordance with Exhibit 1.4. Baxa must obligate each customer that
purchases a Device from Baxa to also purchase the first year of Annual Support
from Baxa to cover the one-year period after expiration of the applicable
ninety-day warranty period described above, and Baxa shall likewise purchase the
first years' Annual Support covering such period for such Device from CDEX.
Purchase of Annual Support for any Device beyond the initial year is solely at
Baxa's and its customer's option.
4.6 Installation. CDEX will perform all installation and
implementation services with respect to each purchased Device. CDEX will work
with Baxa, at CDEX's sole cost, to ensure that each Device is installed and
functioning in accordance with the Specifications and will use reasonable
efforts to accommodate each customer's requested time line.
4.7 Request for Information by Third Parties. Baxa shall forward to
CDEX any inquiries by Third Parties that relate to the efficacy, safety or other
medical issues regarding the Products. CDEX promptly shall address such
inquiries and, if the parties elect to respond to such an inquiry, CDEX shall
send copies of all responses to Baxa.
8
<PAGE>
Execution Copy
4.8 Promotional Materials. At Baxa's request, CDEX will provide to Baxa
commercially reasonable quantities of CDEX Promotional Materials as are required
to enable Baxa to create the Baxa Promotional Materials. Baxa shall be
responsible to ensure that the Baxa Promotional Materials (whether or not based
on the CDEX Promotional Materials) are appropriately tailored for use within
Canada.
4.9 Training. CDEX will, once or twice (at Baxa's option) each
Calendar Year, provide on-site training regarding the Products and their
capabilities for a reasonable number of Baxa sales personnel (not to exceed 20
people at any one training session without CDEX's prior written approval) at a
location designated by Baxa. CDEX will bear the travel and living expenses
required to furnish a trainer to conduct such training. Baxa shall bear all
other associated expenses. The initial training session will be held within
sixty (60) days after the Effective Date as mutually agreed, and follow-on
training sessions will be held on a mutually agreeable schedule.
ARTICLE 5 ORDERS, SHIPMENT AND DELIVERY OF, AND PAYMENT FOR PRODUCTS
5.1 Purchase and Sale of Products. Baxa shall purchase Products from
CDEX, and CDEX shall manufacture, sell and supply to Baxa, Products ordered by
Baxa pursuant to Section 5.2.
5.2 Purchase Orders.
(a) Purchase Orders.
CDEX to Demonstrate Validation of Flu Vaccine and Flu Medications at The American Society of Health Systems Pharmacists (ASHP) MidYear Clinical Meeting, December 4-8
11/14/2005 6:23:01 PM
http://www.marketwatch.com/tools/quotes/newsarticle.asp?guid={F5B77628-F1D1-4C3E-9743-487D569DCAD3}&...
ROCKVILLE, Md., Nov 14, 2005 (BUSINESS WIRE) -- CDEX Inc. (CEXI), developer of the ValiMed(TM) Medication Validation System and other innovative substance detection and verification systems, announces its participation in the 40th MidYear Clinical Meeting of the American Society of Health Systems Pharmacists (ASHP) December 4-8, 2005 in Las Vegas. At ASHP, CDEX will be demonstrating its ValiMed Medication Validation System, and demonstrating how CDEX technology can be utilized to validate authentic influenza vaccine and Tamiflu medication. Counterfeiting of influenza remedies and many other medications and vaccines is a growing problem.
In addition to anti-counterfeiting capabilities, CDEX's ValiMed System is being deployed by health-system pharmacists nationwide to verify compounded medications, correct dosages, and to validate narcotics returns.
CDEX will be located at ASHP Booth 1021 to demonstrate ValiMed's validation capabilities. Jim Griffin, COO, and Jerry Blair, VP of Business Operations, will be available for interviews.
In addition to demonstrations at the CDEX booth, the ValiMed solution will be highlighted at the following presentations at ASHP:
-- Presentation: Wednesday, 12/7/2005, 3:00 p.m. Use of Spectroscopy to Enhance Safety in IV Compounding, James G. Stevenson, Pharm.D., Director of Pharmacy Services, University of Michigan Health System, Ann Arbor
-- Poster: Monday, 12/5/2005, 2:00 p.m. Board 135, Improving medication safety: use of spectral medication validation in high risk intravenous medication (IV) compounding in a pediatric hospital pharmacy, Hanna Phan, Deborah Pasko, John F. Mitchell, Denise K. Glenn, Diane S. Shoemaker, James G. Stevenson
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of materials). CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc., Rockville
by
Wills & Associates
Brad Wills, 301-346-7398
bwills@wills-pr.com
Copyright Business Wire 2005
Latest CDEX Press Releases.......
http://www.cdex-inc.com/pr.html
PRESS RELEASES
•CDEX and Baxa Sign Distribution Agreement Nov. 10, 2005
•BAXA and CDEX Announce Strategic Alignment Nov. 2, 2005
•CDEX’s ValiMed Unit Selected to Validate Controlled Substance Returns Oct. 13, 2005
•Maricopa Medical Center Selects CDEX’s ValiMed Technology for End Product Testing Oct. 12, 2005
•CDEX Announces Implementation and Acceptance of its ValiMed Patient Safety Solution Sept. 29, 2005
•CDEX Announces New Chief Operations Officer Sept. 19, 2005
•CDEX Begins Trading on OTCBB April 14, 2005
•University of Utah Health Sciences Center Addresses Narcotics Diversion Jan. 26, 2005
•CDEX Announces Dallas Children's Medical Center Acceptance of ValiMed Impaired Clinician Solution Jan. 14, 2005
•CDEX Announces New Vice President of Business Operations Jan. 3, 2005
•CDEX Announces Land Mine Contract with US Army June 3, 2002
•CDEX Announces Independent Verification Testing of Explosive Detection Technology May 21, 2002
•CDEX-Inc. Issues Test Reports on the EM-1 Sept. 5, 2001
Apparently the "Great Censor" on the other board doesn't feel I should post the addy to the True CDEX Longs board.
Hmmm. He's not being very kosher.
Let's see him delete it from this board.
http://ragingbull.lycos.com/mboard/viewclub.cgi?board=CLB01212
pCf
Hi Inet. I have asked a couple of times, and get no response. The (old) was added when the other board got a new moderator. Hmmmmmmmmmm! No favorites here. LOL
I know many longs who have told me that they wont post on that board with the current moderator. Not much I can do. Sorry, I have tried.
Viking why don't you get that CDEX (old) off and change it to
something else.
Did Matt stick you with the old when his buddies started their bashing board?
That board is a defensive board,you can't post intelligent stuff there, without it being torn apart just for spite. And if the joker comes back, one can not post without ridiculous censorship.
You can't expect the bashers to disappear forever,from the other I hub board it's not in their makeup. They'll probably be around at $10.00 PS, saying it is not happening.LOL
There is certainly nothing old about CDEX.
Suggestion, Make it the CEXI(CDEX) board
CDEX and BAXA Sign Distribution Agreement (HUGE NEWS)
11/10/2005 9:00:05 AM
ROCKVILLE, Md., Nov 10, 2005 (BUSINESS WIRE) -- CDEX Inc. (CEXI), developer of the ValiMed(TM) Medication Validation System and other innovative substance detection and verification systems, announces a strategic distribution agreement with Baxa Corporation, a leader in developing systems for preparing, handling, packaging, and administering liquid medications. Baxa will be the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
The ValiMed System offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patent-pending technology identifies the medication and strengths to validate compounded doses of high risk medications prior to dispensing. The ValiMed device verifies medications in seconds and provides an added level of safety in the medication dispensing process. The ValiMed System also validates narcotic returns.
"The ValiMed sales required under the Baxa contract, coupled with existing sales and rentals, will solidify the CDEX presence in the medical market and more completely validate our technology for other markets," said Malcolm Philips, CDEX CEO and Chairman. "With Baxa's award-winning customer service and sales teams, we have moved toward that goal in the medical marketplace."
The agreement calls for purchase of a fixed number of ValiMed units by Baxa for two years, as well as goals that must be met in order to maintain the Baxa exclusive distribution rights.
"The ValiMed System fits with Baxa Corporation's mission to offer our customers innovative fluid medication devices that improve operations and increase medication safety. ValiMed is a great addition to our product line," said Greg Baldwin, Baxa Chairman and CEO.
CDEX's mission is to develop innovative technologies that assist in solving real world problems, then work with industry leaders to bring those products to market. For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency.
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternative-site pharmacies. Privately held, Baxa Corporation has subsidiaries and offices in Canada, the United Kingdom and Denmark, and distribution partners worldwide. Further information is available at www.baxa.com.
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of materials). CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc., Rockville
Brad Wills, 301-346-7398
bwills@wills-pr.com
or
Baxa
Marian Robinson, 303-617-2157
marian.robinson@baxa.com
Copyright Business Wire 2005
CDEX's ValiMed......
Michigan Hospital Tests Intravenous Drug Technology
By Christina Orlovsky, senior staff writer
The prevention of medication errors has always been a concern of pharmacists, lab technicians, nurses and physicians. Several new technologies, including bar coding and robotic pharmacies, have helped reduce the risk of error occurring with oral medications, but not much has been done to improve the safety of intravenous drugs—until now. Pharmacists at the University of Michigan’s C.S. Mott Children’s Hospital, in Ann Arbor, Michigan, are piloting a new technology aimed at verifying the identity and concentration of high-risk IV medications.
The ValiMed System, created by ValiMed, Inc., flashes an ultraviolet (UV) light into one-milliliter samples of medication. Each medication has a unique “fingerprint,” called a fluorescence signature, which can be detected in 30 seconds by the UV light, explained Jim Stevenson, Pharm.D., the director of pharmacy services for the University of Michigan Health System. The pharmacists compare the signature with the prescribed concentration before sending the drug out to the patient.
Originally developed to detect explosives, the ValiMed System made its foray into health care in three hospitals that use the technology to test narcotic drug returns in the operating room. C.S. Mott Children’s Hospital is the first facility to use the ValiMed System for this intravenous drug purpose.
“We were looking for a way to make the medication system safer because we know that occasionally, even with experienced pharmacists and technicians, human error can make it past the checks and practices of the hospital pharmacy. Particularly with high-risk intravenous drugs, we wanted to eliminate that human error,” Stevenson said. “When I discovered that the ValiMed System was being used to detect narcotics, I thought, why couldn’t it be used to test high-risk drugs as well?”
Stevenson worked with ValiMed, Inc., to develop the capability and decided the system would work well in the pharmacy setting. In June, the hospital began creating signatures for the top 10 high-risk medications, as determined by the pharmacy staff and a host of published studies. Among these medications are insulin, blood thinners such as heparin, painkillers like morphine and the antibiotic vancomycin. According to Stevenson, all of the medications can produce toxic effects if administered incorrectly.
While the testing of the medications takes place in the pharmacy, the ValiMed System also has an enormous impact on the nursing staff.
“From a nurse’s perspective, when an error happens in the pharmacy with intravenous drugs, there is no way for a nurse to detect and prevent that error because they are dealing with clear liquids. Nurses have to trust that the drug that’s in the bag and its concentration are correct, and they have no way to head it off if it’s not,” Stevenson explained. “This system gives them some added peace of mind and another layer of security to make sure their patient is getting the right drug and concentration.”
For more information, visit the ValiMed Web site.
Viking: delete every post of his, or he will contaminate this board also.
He's the only one seriously talking scam, liars, and bad management,why give him the floor,while aggravating everyone else.
He can delete at will on his board,you should reciprocate.
This can be a much livlier board now,since people will stop throwing up on the other board.
I put this URL on his board last night, but it didn't survive.
TO all: FWIW
From what I've read and researched..I think CDEX is now part of a VERY well run organization. They are involved in many areas of the healthcare system...They have very deep pockets and IMOP see a very bright future for CDEX.
IMOP..This should validate CDEX in the investment community.
TX and I feel better about our investment than we have ever felt...IF we could we would average down..but that's not an option for us at this time.
Hats off to MP and team!!!
Godspeed to all LONGS!!!
Baxa invests $1.5M in CDEX!
http://denver.bizjournals.com/denver/stories/2005/10/31/daily40.html?jst=b_ln_hl
Baxa Corp. has invested $1.5 million in CDEX Inc., and earned a seat on its board, the companies announced Wednesday.
The equity investment by the Denver-based Baxa Corp. also allows for an additional $1 million investment in CDEX (OTCBB: CEXI) over the next nine months. The world-wide privately held company manufactures medical devices and systems for preparing, handling, packing and administering liquid medications.
"This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market," said Greg Baldwin, Baxa's chairman and CEO.
CDEX is a development company that focuses on using chemical detection and validation technology. Currently the company is working with homeland security in identifying substances like illegal drugs and explosives and validating substances to prevent counterfeit or sub-par prescription medications. They are based in Rockville, Md. with its research and development laboratory in Tucson, Ariz.
Baxa Press Releases...
This tells us more about the company we are dealing with..
http://www.emediawire.com/releases/2005/5/prweb239166.php
* New batch syringe filler from Baxa Corporation takes a manual system and automates it, helping eliminate touch contamination. 2003-06-23
* Baxa Corporation Introduces PhaSeal®, The Only Closed System For Safe Handling of Hazardous Drugs 2003-06-26
* Baxa Corporation Announces Recent Chairman and President Promotions Within Its Leadership Team 2003-06-27
* Baxa Corporation Completes Relocation to New US Headquarters 2003-07-08
* MD Anderson and PhaSeal®: A Leader in Science Leads Adoption of New Closed System Technology For Safe Handling of Hazardous Drugs 2003-07-31
* Premier Awards Group Purchasing Agreement for Baxa Compounders 2003-09-20
* Healthcare Workers At Risk: Researchers at Utah's Huntsman Cancer Institute Demonstrate Biological Uptake of Chemotherapy Drugs. 2003-11-20
* Baxa Corporation Sponsors Symposium to Discuss Environmental Exposure and Biological Uptake of Antineoplastics at December ASHP in New Orleans 2003-11-28
* Baxa Corporation Introduces Abacus TPN Calculation Software -- for order entry and total parenteral nutrition calculation. 2003-12-08
* The future of Syringe Infusion: What's New in an Old Application? A Manufacturer's Q&A. 2004-01-11
* Baxa Introduces New Information-Based Web Site for Pharmacy Fluid-Handling and Safe Practice 2004-01-28
* Baxa Corporation sponsors best practices sessions at the National Home Infusion Association's (NHIA) annual conference on infusion safety, quality management, patient education and effective mentoring 2004-03-03
* Baxa Praises NIOSH for Alert on Preventing Occupational Exposure to Hazardous Drugs 2004-03-29
* Baxa to Sponsor Miami Symposium on Environmental Exposure and Biological Uptake of Antineoplastics 2004-04-19
* Baxa Corporation Recertified to ISO 13485 and EN46001 2004-04-30
* Baxa to Sponsor Los Angeles Symposium on Environmental Exposure and Biological Uptake of Antineoplastics 2004-05-12
* Baxa to Feature the PhaSeal(r) Closed System For Safe Handling of Hazardous Drugs at ASCO Annual Meeting in New Orleans June 5-8, 2004 2004-05-26
* Baxa Corporation Completes Six Sigma Training for Problem-Solving and Process Improvement 2004-06-11
* Baxa to Feature the PhaSeal(r) Closed System For Safe Handling of Hazardous Drugs at ASHP Summer Meeting in Las Vegas, NV 2004-06-21
* Baxa Exacta-Med® Dispensers: the World's First Dispenser Designed Specifically for Safe Delivery of Oral Medications is Now Available for Home Use in the UK 2004-07-28
* Expert Sources and Information On Hazardous Drug Handling Are Now Available for Media Access at Expert411.com 2004-07-29
* Baxa to Feature Exacta-Med® and PhaSeal® Systems For Safe Handling and Administration of Fluid Drugs at the Pharmaceutical Marketing Congress in Philadelphia 2004-09-27
* Brian Baldwin, Baxa Corporation Founder, Recognized as Medical Device Industry Pioneer 2004-09-17
* Baxa Names Jim Osgood as Vice President of Product Planning, Research and Development 2004-09-22
* Baxa Corporation Introduces ShrinkSafe® Paralytic Identification Bands for High-Alert Medications 2004-09-23
* NIOSH Publishes Alert On Preventing Occupational Exposure to Hazardous Drugs 2004-09-24
* Nursing Perspective On Hazardous Drug Handling Publishes in the Online Journal of Issues in Nursing 2004-10-23
* Baxa Launches CyTwo-Fer™ Needle - Unique Dual-Purpose Device for Safe Reconstitution of Hazardous Drugs 2004-11-03
* Baxa Sponsors Exhibitor’s Theatre on Avoiding Costly Mistakes in Complying with the Requirements of USP 797 2004-12-02
* Baxa Sponsors Exhibitor’s Theatre on Reducing Environmental Exposure to Hazardous Drugs at ASHP Mid-Year Meeting 2004-12-01
* Baxa Corporation Honors Texas Children’s Hospital in Houston with 2004 Best Practices Award 2004-12-09
* Baxa Introduces New Amber Oral Dispenser Packaging for Ward and Bedside Applications 2005-03-07
* "Understanding USP 797" and "Environmental Controls for Sterile Compounding" Technical Papers are Now Posted on PublicRelationsNewsroom.com In Light of the Continued Regulatory Focus on Hazardous Drug Handling in the Workplace 2005-01-30
* Baxa Corporation Expands Headquarters Facilities 2005-02-27
* Cleanrooms: A Question & Answer Document from Baxa Corporation is Now Posted on PublicRelationsNewsroom.com for Media and Professional Access In Light of the Continued Regulatory Focus on Hazardous Drug Handling in the Workplace 2005-02-27
* Baxa Introduces Four New Microfuse Infusion System Administration Sets 2005-03-18
* Baxa Corporation Celebrates 30 Years of Product Safety and Innovation for Hospital Pharmacies 2005-03-24
* Baxa CEO Greg Baldwin Joins Healthprolink Board of Directors 2005-03-30
* Baxa CEO Greg Baldwin Is Now Profiled at the Expert Information for Journalists Website and Available to Address Selected Business Topics 2005-04-02
* Baxa Features Exacta-Med® And PhaSeal® Systems For Safe Handling And Administration Of Fluid Drugs At Interphex 2005 2005-04-26
* Baxa Corporation Introduces New PhaSeal® System Component For Accessing Needleless Connectors 2005-05-02
* Baxa Corporation Honored with Two American Inhouse Design Awards in The National 2005 Competition Sponsored by Graphic Design USA 2005-05-07
* Baxa Corporation Awarded Colorado Governor’s Award For Excellence In Exporting 2005-05-16
* Family Business Experts Credits Family Business Synergy As Key To Baxa Corporation’s Success 2005-05-23
* Baxa Corporation Receives Small Business Exporter Of The Year Award 2005-05-30
* Baxa Corporation Announces Direct Sales And Marketing Effort In Canada Beginning June 1 2005-05-31
* Baxa Sponsors Team In Courage Classic Fundraiser For The Children’s Hospital 2005-06-03
* Baxa Corporation Awarded Best Sales Team in 2005 American Business Awards 2005-06-10
* Baxa Corporation’s Brian Baldwin Selected as Finalist for Ernst & Young 2005 Entrepreneur of The Year® Awards 2005-06-16
* Baxa Corporation’s Brian Baldwin Wins Ernst & Young 2005 Entrepreneur Of The Year® Award 2005-06-26
* Baxa Corporation’s Jeff Baldwin Provides Business Perspective To Denver’s 9News Regarding UK Terrorist Attacks 2005-07-16
* Baxa Corporation’s CEO Greg Baldwin Tours Gregg Moss of 9News Through The Company’s Sterile Medical Device Manufacturing Facilities on 'Where In The Town Is Gregg Moss' 2005-07-24
* Baxa Corporation Announces Compliance To The European Directive On Waste Electrical And Electronic Equipment 2005-08-17
* Baxa Corporation Named as Colorado Top Company Finalist 2005-08-27
* Nutrition Therapy and Continuous Infusion Case Studies From Baxa Corporation Now Available for Media Access 2005-09-02
* Exacta-Med® Oral Dispensers Eliminate Wrong-Route Errors And Inappropriate Clinical Line Connections 2005-09-02
* Baxa Repeater™ Pump Validated in Hydrogen Peroxide Vapour Sterilisation Tests 2005-09-08
* Baxa Corporation Honored as Colorado Top Company 2005-09-10
* Baxa Introduces New Oral and Enteral Liquid Dispensers with Purple Plungers to Increase Patient Safety 2005-09-13
* Baxa Corporation Receives Design Award from Art Directors Club of Denver 2005-10-03
* Process Changes at Lucile Packard Children’s Hospital Result in Safer and More Efficient Nutrition Compounding 2005-10-31
Why is that OT? Diddy, sandollar, crow talk about all kinds of things on your board, and you never say a word about OT to them. Yet thge shareholders of CDEX don't have the same rights? It is obvious that you are favoring the non shareholders!
Viking65, do you know what O/T stands for?
INET is says in the paragraph below that BAXA will be offered a seat on the CDEX board of directors. They are obviously linked very deeply with CDEX. With BAXA, CDEX has all there connections to approx. 4,000 hospitals. BAXA is a very pivital key to the future success of CDEX. It would seem obvious to any CDEX shareholder that wants to see CDEX succeed, that they would be interested in information about BAXA. To keep that information off the CDEX message board, and let the non shareholders post endlessly about Loch Harris (a dead issue) is not fair and balanced. As Loch Harris has nothing to do with the future of CDEX.
Englewood, CO and Rockville, MD – November 2, 2005 – Baxa Corporation and CDEX Inc. (OTCBB: CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a "seat on the CDEX Board of Directors".
Viking65, As moderator of this board I would like to ask you to intercede with Matt on why this post was deleted from the CEXI board. Morovan has it in his head that posters can not talk about Baxa.
These are my words,Viking For what they are worth!
This post was deleted with 13 minutes to go.
Are these Investor hub boards becoming a joke?
message 8360990 is a deleted message!!!
lMorovan as moderator and Matt as administrator of Investorshub
The only reason anyone spams a board is to increase the appearance of value to increase share prices.
Since Baxa is a private company there is no purpose in spamming it.
The only reason Baxa is mentioned on this board is to show it's value to CDEX. By the same token Baxa's name and position in the marketplace is of great interest to future potential investors.
For instance ,until yesterday practically no one even knew of Baxa. Now we want to find out all we can about our investing saviour. The way we can all be aware of what Baxa means to us and its potential value to CDEX is to have everything that can be found be posted on these boards.
One would be selfish to find something about Baxa and not share it with the shareholders and posters.
Now morovan, we mostly all realize that this potential for success is eating at your craw,and if you insist on this boycott of our investing partner, Matt would be less than efficient as an administrator to allow you to continue.
INET that is a great post! Thanks! BAXA is a great company, and I am glad CDEX is with them. What a wonderful business connection. Certainly validates CDEX doesn't it. Not that I had a problem with that.
Posted by: INET6
The vaue of this buy in, IMO is tremendous for both parties.
CDEX does not have to design and promote ,nor seek FDA approval for injectionablle mixtures. Baxa all ready has their foot well into the door. Without a doubt even with Baxa's equipment pharmacies have at times made a bad mixture and now they have the answer. Just imagine Baxa selling their mixing apparatus to pharmaceuticals and suggesting a ValiMed unit for complete assurance.
From google
Automated Filling Systems
Collection Bags, Large-Volume Filters, Pump Accessories, Repeater™ Pump, Rapid-Fill™ Automated Syringe Filler, Robotic Filling System, Scale, Syringe Strips, Syringe Filling Fixture, Top Fill Bags, Tube Sets now add ValiMed
Multi-Ingredient Solution Compounding
Abacus™ Software, Adapters, Caps, Connectors, Dual-Chamber TPN Bags, Exacta-Mix™ 2400 and 600 Compounders, Gravity Mixing Sets, Inlets, MicroMacro™ 12 and 23 Compounders, TPN Bags, Tube Sets, Valve Sets, Vial Racks now add ValiMed
IV Administration
Administration Sets, MicroFuse® Accessories, MicroFuse Infuser, MicroFuse Extended Rate Infuser, MicroFuse Rapid Rate Infuser now add ValiMed
IV Admixture
Collection Bags, Dispensing Pins, Needles, Port Saver, Rapid-Fill Connectors and Adapters, Syringes, Syringe Filters, Tamper-Evident Seals, Tip Caps, Transfer Needles, Two-Fer™ Needles, Vent Filters, Venting Pins
Oral Liquid Delivery Systems
Adapta-Cap™ Bottle Adapters and Bottlewells, Exacta-Med® Oral Dispensers and Accessories, Enteral Syringes, Gel Bags, Kwik-Vial™ Containers and Accessories, Kwik-Vial Software, Labels, Mark-a-Dose™ Labels, Tamper-Indicating Seals, Rapid-Fill Oral Connectors, Press-In Bottle Adapters, 3-Way Oral Port Sto
IMO Baxa knew what they were doing and now CDEX's scientists can concentrate on other uses of the tech.
About BAXA Corperation-very impressive.
http://www.hpc-world.com/content_archives/Fall05/06.html
Although it is more than 25 years old, Baxa Corp. says it has just begun to deliver innovative devices for oral drug delivery systems, IV admixture and administration, and solution compounding. By Hanna Aronovich
Colorado-based Baxa Corp. plans to double in size in the next five years by maximizing its internal resources. The company says it plans to do more with less and continue as an efficient provider of healthcare technology. Baxa Corp. was founded in 1975 by Brian Baldwin and Ronald Baxa. At the time, the company explains, oral liquid medications were dosed with teaspoons or graduated cups, which often resulted in inaccurate and sometimes dangerous doses. Additionally, the use of luer syringes to deliver non-sterile oral liquid medications raised the possibility of accidental injection.
Baxa Corp. introduced the Exacta-Med® Oral Dispenser in 1975. With a special tip that does not accept a needle, Exacta-Med Dispensers were designed to provide an accurate, completely safe method for dosing oral liquid drugs. The Exacta-Med Dispenser quickly became the industry standard, and remains a key part of the Baxa Corp. product line today.
CEO Greg Baldwin says Baxa Corp. has seen growth in its three major business lines: oral drug-delivery systems, IV admixture and administration, and multi-ingredient solution compounding. Success, however, creates challenges. “We need to make sure not to get complacent, so we have organized the company to promote continued success,” he says.
Baldwin acknowledges Baxa Corp. is a smaller company compared to others in the medical device arena, and “the only reason to do business with us rather than the larger companies is because our products are innovative,” he says. “We add value and solve problems better than the competition. We work hard to get to know our customers, and that translates into market knowledge and innovative solutions. Our customers challenge us to do more.”
Baldwin says Baxa Corp. works with approximately 4,000 hospitals – primarily pediatric, tertiary care and teaching hospitals. The United States represents more than 50 percent of the worldwide medical device marketplace, and Baldwin says approximately 80 percent of Baxa Corp’.s sales are domestic, while the remaining 20 percent are international sales. “We want to build lifetime relationships with companies around the world,” he stresses. “We're not just selling a product and moving on. We bring a system into a hospital and are there to meet their needs for the long haul. That's a key component to our success.”
Baxa Corp. compensates salespeople not simply for completing a sale, but for maintaining relationships. Sales representatives help customers determine exactly what medical devices they need, and guide them away from products they don't. “They take a real interest in our customers, and we reinforce that message in our training.”
Baxa Corp. identifies its customers' problems and works closely to develop solutions. Customer task forces are one way Baxa Corp. determines what products the market needs. For example, in 2003, Baxa Corp. developed the Rapid-FillTM Automated Syringe Filler, the first system designed to automate sterile batch filling in the pharmacy. Automating the process of filling, capping and labeling sterile syringes minimizes the potential for contamination and reduces pharmacy overhead. Additionally, the Rapid-Fill system increases efficiency and cost-effectiveness by filling up to 1,000 syringes an hour.
Baldwin says Baxa Corp.'s flagship product is the Exacta-MixTM 2400 Compounder, which allows pharmacies to mix up to 24 discrete ingredients into an IV nutritional solution. The companion AbacusTM Software system, a Windows-based order entry and calculation program, processes the specific prescription for use with the Exacta-Mix and other compounders.
Introduced in March 2002, Baldwin says Baxa Corp. went from the No. 2 player to the No. 1 player in the market because of the Exacta-Mix and Abacus Software systems. “About 25 percent of the tertiary care and acute care hospitals use our system, and we are thrilled about that,” he notes.
Baldwin also points to the PhaSeal® products, a closed system that allows for the safe handling of hazardous drugs. He says this product makes up more than 10 percent of Baxa Corp.'s sales. Training and operational excellence are key components to Baxa Corp.'s innovation. Baxa Corp. holds GMP training sessions, so every person in the organization understands the company's responsibilities. Baldwin says all new employees undergo a three-day, intensive new-employee orientation program, which reviews various topics depending on the employee's position.
Management and supervisory training is also a company priority, and Baldwin says managers attend several courses throughout the year to review topics in good management. The company organizes small peer groups so employees can review training topics in greater depth, share personal experiences and work together to solve problems.
Successful Endeavors
In 2003, Baxa Corp. opened a new, 93,000-square-foot facility with an 8,000-square-foot ISO Class V cleanroom. Baldwin says the upgrade allowed Baxa to expand considerably. “In 2003, we grew 24.9 percent,” he notes. “Last year, we grew 29 percent, and this year, we're on track to see a 25 percent increase in growth.”
From its initiatives, Baxa Corp. has nearly achieved its long-time goal of earning $100 million in sales. The company plans to double this figure in the next five years.
“We've been around for 30 years, and we're doing a lot of soul searching,” Baldwin says. “My father, Brian Baldwin, is the founder and vice chair of the company and Jeff Baldwin is my brother and the COO. Between the three of us, we decided that the business has only just begun, and we're focusing on bringing more processes into the 21st century of technology.” HPC
Businesswire link and article about BAXA & CDEX. The news is everywhere.
Baxa and CDEX Announce Strategic Alignment
http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051102005...
ENGLEWOOD, Colo. & ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 2, 2005--Baxa Corporation and CDEX Inc. (OTCBB:CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a seat on the CDEX Board of Directors. (For additional details, see CDEX's 8K filed with the SEC.)
"We are pleased that Baxa has invested in CDEX and view this decision as a first step toward strategic alignment between Baxa and CDEX," states Malcolm Philips, CDEX's Chairman and CEO. "Baxa is a well-respected name in the medical community and its investment in CDEX will facilitate faster expansion into that and other markets."
"We looked closely at CDEX and found a technological and cultural alignment with our business and values," said Greg Baldwin, Baxa's Chairman and CEO. "This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market. We welcome the opportunity to work with CDEX in the future."
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom, Denmark, and Germany and distribution partners worldwide. Further information is available at www.baxa.com.
Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email: Marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jerry Blair at 301.881.0080 (jblair@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
BAXA Invests $1.5 Million in CDEX!
http://denver.bizjournals.com/denver/stories/2005/10/31/daily40.html?jst=b_ln_hl
Baxa invests $1.5M in CDEX
Baxa Corp. has invested $1.5 million in CDEX Inc., and earned a seat on its board, the companies announced Wednesday.
The equity investment by the Denver-based Baxa Corp. also allows for an additional $1 million investment in CDEX (OTCBB: CEXI) over the next nine months. The world-wide privately held company manufactures medical devices and systems for preparing, handling, packing and administering liquid medications.
"This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market," said Greg Baldwin, Baxa's chairman and CEO.
CDEX is a development company that focuses on using chemical detection and validation technology. Currently the company is working with homeland security in identifying substances like illegal drugs and explosives and validating substances to prevent counterfeit or sub-par prescription medications. They are based in Rockville, Md. with its research and development laboratory in Tucson, Ariz.
Baxa and CDEX Announce Strategic Alignment
11/2/2005 12:00:01 PM
ENGLEWOOD, Colo. & ROCKVILLE, Md., Nov 02, 2005 (BUSINESS WIRE) -- Baxa Corporation and CDEX Inc. (CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a seat on the CDEX Board of Directors. (For additional details, see CDEX's 8K filed with the SEC.)
"We are pleased that Baxa has invested in CDEX and view this decision as a first step toward strategic alignment between Baxa and CDEX," states Malcolm Philips, CDEX's Chairman and CEO. "Baxa is a well-respected name in the medical community and its investment in CDEX will facilitate faster expansion into that and other markets."
"We looked closely at CDEX and found a technological and cultural alignment with our business and values," said Greg Baldwin, Baxa's Chairman and CEO. "This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market. We welcome the opportunity to work with CDEX in the future."
About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom, Denmark, and Germany and distribution partners worldwide. Further information is available at www.baxa.com.
Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email: Marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jerry Blair at 301.881.0080 (jblair@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc.
Jerry Blair, 301-881-0080
jblair@cdex-inc.com
Mr. Griffin may have breached his employment agreement by not fulfilling the requirement to purchase 300,000 shares of CDEX, and CDEX may have breached its fiduciary duties by not setting up both the price and the date the purchase must be executed.
Very impressive. For the life of me I cannot figure out why we have gone nowhere in the bomb detection arena, given the comments in this video.
Will we ever know the answer?
Blackdog
Great link for Valimed! Play the video and read the story.
http://wfrv.com/seenon/local_story_299115222.html
New Machine Helps Get Right Drug Doses
Lisa Malak
Reporting
Save It Email It Print It
(CBS News) ANN ARBOR, MI I-V Medicines Don't Always Come In Kid-Sizes.. And That Means Pharmacists Have To Mix The Drugs Themselves.
But There's New Help From A Surprising Source.
Bomb-Sniffing Technology Can Get The Dosage Just Right.
Valimed/Ann Arbor, MI
Jim Stevenson Says This Blue Machine At His Pharmacy.. Provides Peace Of Mind.
Jim Stevenson, PharmD/Univ. Of MI Children's Hosp.
"Particularly In A Pediatric Hospital Where You've Got High- Risk Drugs And Very Small Patients."
Even The Smallest Mistake Can Be Deadly.. But Valimed Takes Human Error Out Of The Equation.
Jim Stevenson, PharmD/Univ. Of MI Children's Hosp.
"We Put A Small Sample Of The Product We Wanna' Test Into The Device. It Shoots Ultraviolet Light At The Sample."
The Machine Compares The Sample To What's Called The "Fingerprint" Of The Medication.
If The Dose Is Mixed Right?
"Validated."
Jim Stevenson, PharmD/Univ. Of MI Children's Hosp.
"This Technology Was Initially Devised To Help Detect Explosive Devices With Homeland Security."
The University Of Michigan's Children's Hospital Is The First In The Country To Use Valimed.
Phil Mapes/Father Of Heart Patient
"It's Comforting To Know That They're Taking The Extra Step."
Phil Mapes' Daughter Meggan.. Is A Heart Patient.. Who Receives Several High-Risk Medications.
Phil Mapes/Father Of Heart Patient
"Dopamine, She's On Morphine For Pain. I Don't Know What They All Are But There's A Bunch Of Different Ones, Yeah."
Making Sure She Gets The Right Medicine In Her I-V.. Is Now One Less Thing Her Parents Have To Worry About.
The Pharmacy Is Still In The Process Of Adding New Medications To The System.
Viking65, I pointed out, on the CDEX board, at least 8 errors or misleading information in the article. Not opinions of mine, but pure facts. Now, if you don't want to see them is not my fault.
lmorovan you contain errors and misleading statements.
Viking65, the article contains errors and misleading statements, even as CDEX paid for it.
Waterville Research Investments about Cdex.
http://www.watervilleresearch.com/companies/development/247-1.html
Medication Errors in the U.S.
WHOI-TV Illinois Report
Healthbeat:Valimed
October 20, 2005
Jen Christensen
A medication error is defined as the unintentional administration or use of a drug that could potentially cause harm to the patient. The error may involve providing the wrong drug, giving the wrong dose, administering the wrong form (for example, direct injection of a medication meant to be diluted in an intravenous solution), or not providing medication at the right time.
According to a survey by the Commonwealth Fund, about 16 percent of Americans have experienced a prescription drug error or have a family member who experienced an error. In about 20 percent of cases, the mistake caused a serious problem for the affected patient (like prolonged hospitalization or death).
There are many steps involved from the time a physician orders a prescription until the patient gets the drug. A medication error can be made at any point in the process. Written prescription orders may not be legible, causing a patient to get the wrong drug, wrong dose, or wrong method or timing or administration. Verbal orders may also cause confusion when the pharmacist mistakes sound-alike drugs. Nurses may pull the wrong medication from the shelf or fail to verify the correct medication/dose/route with the patient’s chart. Use of abbreviations can cause further confusion and increase the chance of a drug mix-up.
The ValiMed™ System
All those involved in providing medications to patients are supposed to double-check each prescription order before giving the patient the medication. However, the best-planned systems can still lead to mistakes. Even computerized checks can be imperfect due to human error.
Researchers have developed a new type of drug checking system to verify the correct medication in a prepared drug sample. The technology, called ValiMed™, was first developed to detect explosives. The ValiMed sits on the countertop of the pharmacy. When a medication is mixed, a tiny sample is placed in the machine. ValiMed flashes an ultraviolet light onto the drug. When exposed to the light, the molecules in the sample produce a pattern of fluorescent energy. Every drug has a unique pattern of fluorescence, creating a drug fingerprint. The ValiMed reads the fluorescent fingerprint and compares it against known drug fingerprints in a data library. If the test doesn’t show a match, the sample is retested. If the drug can’t be validated in the second attempt, it’s sent back to the lab.
The University of Michigan Health System is the first hospital in the world to use ValiMed for verifying the identity of prescription drugs. The hospital pharmacy is currently using the system to test 10 commonly used high-risk drugs that are specially prepared for children. Other drugs will be added to the database in the future. For information about the ValiMed system, log on to the website at http://www.valimed.com/.
AUDIENCE INQUIRY
For information on ValiMed™, http://www.valimed.com/
For general information on medication errors and prevention:
Agency for Healthcare Research and Quality, http://www.ahrq.gov/qual/errorsix.htm
American Society of Health-System Pharmacists, public website, http://www.safemedication.com
The Commonwealth Fund, http://www.cmwf.org
The Food and Drug Administration, Center for Drug Evaluation and Research, http://www.fda.gov/cder
Institute for Safe Medication Practices, http://www.ismp.org
National Coordinating Council for Medication Error Reporting and Prevention, http://www.nccmerp.org
Source: http://www.hoinews.com/news/features/3/1768121.html
ValiMed On another news station out of IL. Oct. 20, '05
http://www.hoinews.com/news/features/3/1768121.html
Healthbeat:Valimed
October 20, 2005
Jen Christensen
Medication Errors in the U.S.
A medication error is defined as the unintentional administration or use of a drug that could potentially cause harm to the patient. The error may involve providing the wrong drug, giving the wrong dose, administering the wrong form (for example, direct injection of a medication meant to be diluted in an intravenous solution), or not providing medication at the right time.
According to a survey by the Commonwealth Fund, about 16 percent of Americans have experienced a prescription drug error or have a family member who experienced an error. In about 20 percent of cases, the mistake caused a serious problem for the affected patient (like prolonged hospitalization or death).
There are many steps involved from the time a physician orders a prescription until the patient gets the drug. A medication error can be made at any point in the process. Written prescription orders may not be legible, causing a patient to get the wrong drug, wrong dose, or wrong method or timing or administration. Verbal orders may also cause confusion when the pharmacist mistakes sound-alike drugs. Nurses may pull the wrong medication from the shelf or fail to verify the correct medication/dose/route with the patient’s chart. Use of abbreviations can cause further confusion and increase the chance of a drug mix-up.
The ValiMed™ System
All those involved in providing medications to patients are supposed to double-check each prescription order before giving the patient the medication. However, the best-planned systems can still lead to mistakes. Even computerized checks can be imperfect due to human error.
Researchers have developed a new type of drug checking system to verify the correct medication in a prepared drug sample. The technology, called ValiMed™, was first developed to detect explosives. The ValiMed sits on the countertop of the pharmacy. When a medication is mixed, a tiny sample is placed in the machine. ValiMed flashes an ultraviolet light onto the drug. When exposed to the light, the molecules in the sample produce a pattern of fluorescent energy. Every drug has a unique pattern of fluorescence, creating a drug fingerprint. The ValiMed reads the fluorescent fingerprint and compares it against known drug fingerprints in a data library. If the test doesn’t show a match, the sample is retested. If the drug can’t be validated in the second attempt, it’s sent back to the lab.
The University of Michigan Health System is the first hospital in the world to use ValiMed for verifying the identity of prescription drugs. The hospital pharmacy is currently using the system to test 10 commonly used high-risk drugs that are specially prepared for children. Other drugs will be added to the database in the future. For information about the ValiMed system, log on to the website at http://www.valimed.com/.
AUDIENCE INQUIRY
For information on ValiMed™, http://www.valimed.com/
For general information on medication errors and prevention:
Agency for Healthcare Research and Quality, http://www.ahrq.gov/qual/errorsix.htm
American Society of Health-System Pharmacists, public website, http://www.safemedication.com
The Commonwealth Fund, http://www.cmwf.org
The Food and Drug Administration, Center for Drug Evaluation and Research, http://www.fda.gov/cder
Institute for Safe Medication Practices, http://www.ismp.org
National Coordinating Council for Medication Error Reporting and Prevention, http://www.nccmerp.org
NOW FOR NEW NEWS TODAY ON CDEX/VALIMED:HERE ARE THE LINKS.
Advanced Chemical Sensors Co.
http://www.endonurse.com/articles/5a1innov.html
Michigan Hospital Tests Intravenous Drug Technology
http://www.nursezone.com/job/DevicesandTechnology.asp?articleID=14097
Why was post 364 pulled? It is official information posted on the SEC website.
MP files another Form 4. More insider selling:
http://www.secform4.com/insider/viewform4.php?cik=1173738&dir=000121465905001484&form=s10135...
CDEX/VALIMED TV Channel 6 Omaha, Nebraska.
Methodist Hospital
http://www.wowt.com/news/features/2/1783826.html
Getting The Meds Right
New machine lends electronic hand
I-V medicines don't always come in kid-sizes and that means pharmacists have to mix the drugs themselves. State-of-the-art technology is helping one pharmacist get the dosage just right.
Pharmacist Jim Stevenson says a blue machine that now sits on his pharmacy's countertop provides peace of mind.
"Particularly in a pediatric hospital where you've got high-risk drugs and very small patients," he says.
Pharmacists who mix millions of doses know that even the smallest mistake can be deadly but ValiMed takes human error out of the equation.
Stevenson says, "We put a small sample of the product we want to test into the device. It shoots ultraviolet light at the sample."
The machine compares the sample to what's called the "fingerprint" of that particular medication. If the dose is mixed just right, the machine's confirms that.
Stevenson says, "This technology was initially devised to help detect explosive devices with homeland security."
The University of Michigan's Children's Hospital is the first hospital in the country to use the technology to double-check medicine.
Phil Mapes' 15-year-old daughter Meggan is a heart patient who receives several high-risk medications and Phil says, "It's comforting to know that they're taking the extra step."
The pharmacy is still in the process of adding new medications to the system.
Supplemental Information
Fast Facts
· About 16 percent of Americans have experienced a prescription drug error affecting themselves or a family member.
· More than 20 percent of drug errors have serious consequences.
· Medication errors can occur at any point between the time the drug is prescribed and given to the patient.
· ValiMed is a system to verify a medication sample based on a unique fluorescent fingerprint produced by a drug.
Medication Errors in the U.S.
A medication error is defined as the unintentional administration or use of a drug that could potentially cause harm to the patient. The error may involve providing the wrong drug, giving the wrong dose, administering the wrong form (for example, direct injection of a medication meant to be diluted in an intravenous solution), or not providing medication at the right time.
According to a survey by the Commonwealth Fund, about 16 percent of Americans have experienced a prescription drug error or have a family member who experienced an error. In about 20 percent of cases, the mistake caused a serious problem for the affected patient (like prolonged hospitalization or death).
There are many steps involved from the time a physician orders a prescription until the patient gets the drug. A medication error can be made at any point in the process. Written prescription orders may not be legible, causing a patient to get the wrong drug, wrong dose, or wrong method or timing or administration. Verbal orders may also cause confusion when the pharmacist mistakes sound-alike drugs. Nurses may pull the wrong medication from the shelf or fail to verify the correct medication/dose/route with the patient's chart. Use of abbreviations can cause further confusion and increase the chance of a drug mix-up.
The ValiMedT System
All those involved in providing medications to patients are supposed to double-check each prescription order before giving the patient the medication. However, the best-planned systems can still lead to mistakes. Even computerized checks can be imperfect due to human error.
Researchers have developed a new type of drug checking system to verify the correct medication in a prepared drug sample. The technology, called ValiMedT, was first developed to detect explosives. The ValiMed sits on the countertop of the pharmacy. When a medication is mixed, a tiny sample is placed in the machine. ValiMed flashes an ultraviolet light onto the drug. When exposed to the light, the molecules in the sample produce a pattern of fluorescent energy. Every drug has a unique pattern of fluorescence, creating a drug fingerprint. The ValiMed reads the fluorescent fingerprint and compares it against known drug fingerprints in a data library. If the test doesn't show a match, the sample is retested. If the drug can't be validated in the second attempt, it's sent back to the lab.
The University of Michigan Health System is the first hospital in the world to use ValiMed for verifying the identity of prescription drugs. The hospital pharmacy is currently using the system to test 10 commonly used high-risk drugs that are specially prepared for children. Other drugs will be added to the database in the future. For information about the ValiMed system, log on to the website at http://www.valimed.com/.
Web Resources
· ValiMed
lmorovan is pulling posts left and right. God forbid you should disagree with him. "The gang that couldn't shoot straight", can openly slander people. Make false accusations, and those posts don't get removed?????? Censorship at it's worst!
New PR: CDEX's ValiMed Unit Selected to Validate Controlled Substance Returns
10/13/2005 12:30:01 PM
ROCKVILLE, Md., Oct 13, 2005 (BUSINESS WIRE) -- CDEX Inc. (CEXI) announces that its ValiMed Impaired Clinician Solution to validate narcotic returns from an operating room suite has been selected for use by a major academic medical center in the Chicago area. ValiMed provides a simple and effective way to address the Joint Commission on Accreditation of Healthcare Organizations' standards requiring that all narcotic waste be validated by a pharmacist before disposal.
"The ValiMed system comprises three components: the instrument, a proprietary library of chemical 'fingerprints,' and process automation software. The reporting capabilities of the system can help healthcare organizations document compliance with JCAHO standards for controlled substances," said Malcolm Philips, CDEX's CEO and Chairman of the Board. "We are excited and honored by the growing number of major medical facilities that are selecting the ValiMed patent pending technology to assist them and we look forward to expanding relationships with each of them in the future."
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX Inc.
CDEX Inc.
Jim Griffin or Jerry Blair
301-881-0080
cdexmanagement@cdex-inc.com
NEWS:Maricopa Medical Center Selects CDEX's ValiMed Technology for End Product Testing
Wednesday October 12, 1:00 pm ET
ROCKVILLE, Md. & PHOENIX--(BUSINESS WIRE)--Oct. 12, 2005--CDEX Inc. (OTCBB:CEXI - News) announces that Maricopa Medical Center in Phoenix, Arizona, has selected the CDEX ValiMed Patient Safety Solution to do end product testing of compounded IV medications in its pharmacy department.
ADVERTISEMENT
"We are pleased that Maricopa Medical Center has selected the CDEX ValiMed unit as a tool for end product testing," said Malcolm Philips, CEO and Chairman of the Board for CDEX. "The Maricopa Medical Center offers a great venue to continue to improve our technology. Our list of nationally recognized clients who are using ValiMed continues to grow."
The ValiMed Patient Safety Solution uses light energy and a library of unique spectral fingerprints to validate IV drugs in solution. The device can validate that the correct drug and correct dose has been added to the medication during the compounding process.
About MIHS:
Maricopa Integrated Health System is headquartered in Phoenix. The cornerstone of the system is Maricopa Medical Center (MMC), a major teaching hospital with a history dating back more than 100 years. Best known for its critical care services, the hospital offers Level 1 trauma and intensive care for adults, babies and children. Two in-patient psychiatric care centers with nearly 200 beds provide services in behavioral medicine. The nation's second largest burn treatment facility, the Arizona Burn Center, located on the main hospital campus, treats more than 800 patients per year. Eleven family health care centers are located throughout the Valley, providing primary and specialty care ranging from well baby to HIV-AIDS patient services. For more information: www.mihs.org.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
CDEX Inc., Rockville
Jim Griffin, 301-881-0080
Eagle Broadband Files Lawsuit Against Internet Posters Believed to Be Engaged in Illegal Trading Activities & Stock Manipulation Schemes
Wednesday October 5, 11:30 am ET
Company to Aggressively Seek Damages and Injunctive Relief to Ban Posters from Distributing False, Fraudulent and Misleading Information Designed to Damage the Company, its Shareholders and Stock
HOUSTON--(BUSINESS WIRE)--Oct. 5, 2005-- Eagle Broadband, Inc. (AMEX:EAG - News), a leading provider of broadband, Internet protocol (IP) and communications technology and services, announced today that the company has filed a lawsuit containing claims for defamation and unfair business practices in the Superior Court of California against 25 anonymous "John Doe" defendants alleging that these defendants have distributed false, fraudulent and misleading misinformation on Internet message boards in an effort to damage Eagle's business and its shareholders, and to drive down the value of its stock in order to reap profits for themselves.
ADVERTISEMENT
The 25 "John Doe" defendants named in the lawsuit include individuals using the following Internet message board ID's: "upanddown100", "team_3339", "bubba2o", "benderanddundat", "advanced_headlines", "richwill21", and "phil_phd2003", among others. The company may add additional defendants to this lawsuit as additional evidence warrants.
The company has evidence that these posters have engaged in unlawful activities and is seeking monetary and punitive damages from these individuals and/or firms who have engaged in deliberate misinformation campaigns designed to drive down the price of the company's stock in an apparent attempt to capture illegal gains from short sales.
The fraudulent and misleading information distributed by these defendants has been posted on widely visited financial Internet message boards including Yahoo! Finance, Raging Bull and others. The information has included, but is not limited to, fraudulent statements about the financial condition and business activities of the company, erroneous information about the company's products, partners and customers, and personal attacks against the company's management, board of directors and employees. The lawsuit is designed to stop these individuals and/or firms from continuing these illegal activities as well as to seek the full measure of damages and other remedies permitted by law.
"While Eagle Broadband fully respects individuals' right to free speech, we will not tolerate deliberate misinformation campaigns that disseminate false and fraudulent statements that damage the company, our shareholders and the value of our stock," said David Micek, President and CEO of Eagle Broadband.
Micek continued, "The internal committee we previously formed to investigate improper trading activities has uncovered solid evidence of fraudulent and defamatory information being posted on various Internet sites. While we support the use of the Internet to discuss the company and its progress, we believe it is now appropriate to aggressively pursue all available regulatory and legal remedies against those engaging in these illegal schemes. Our goal is to do everything we can to put a stop to these illegal activities and seek maximum damages for the benefit of Eagle and its shareholders."
"As the company remains focused on growing the business, our internal committee and legal team will continue to closely monitor the online message boards, and we will remain extremely vigilant in our efforts to uncover and take action against any individuals or firms engaged in these illegal activities," Micek added.
OT, In the torah it's much more frequently refered to as Adonai.
Gary
O/T lmorovan, thanks
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
516
|
Created
|
05/17/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |